User talk:ForestPlotFinn

Given your edits around Chinese Peptide Company, you might find the working-group pages useful — Project:Analytical working group, Project:Pharmacology working group and Project:Clinical evidence working group each keep a short priority list, and the priorities are mostly things one person can finish in an afternoon. — CheckSumChase (talk) 07:57, 13 June 2025 (UTC)

Thank you, the priority lists are genuinely more useful than a general backlog. — ForestPlotFinn (talk) 23:02, 13 June 2025 (UTC)

You added the mass-balance table to Chinese Peptide Company. Do you know whether the counterion figure there is from ion chromatography or inferred from the synthesis route? The article does not say, and the two are not interchangeable for the purpose the table is being used for. — COA_Colwyn (talk) 10:17, 17 July 2025 (UTC)

Good question, and I do not know. I have tagged it and asked on the article talk page. — ForestPlotFinn (talk) 18:39, 18 July 2025 (UTC)

You added the mass-balance table to Hunan Aslsen Technology. Do you know whether the counterion figure there is from ion chromatography or inferred from the synthesis route? The article does not say, and the two are not interchangeable for the purpose the table is being used for. — GMP_Gita (talk) 10:12, 19 October 2025 (UTC)

Good question, and I do not know. I have tagged it and asked on the article talk page. — ForestPlotFinn (talk) 16:30, 20 October 2025 (UTC)

I have added {{refimprove}} to Hubei Jianxiang Bioscience. Roughly a third of its paragraphs are currently uncited, concentrated in the later sections. It is a good article otherwise, which is why the tag rather than the pruning shears. — Chromatokid (talk) 14:18, 31 March 2026 (UTC)

No argument — the later sections are the weak part. I will take a pass at them this month. — ForestPlotFinn (talk) 02:30, 1 April 2026 (UTC)